Background
Restenosis after PCI and/or stent implantation still is one of the challenging problems in the field of interventional cardiology. Different concepts to prevent and to treat restenosis including drug-eluting stents with proven reduction of restenosis are developed. Another concept represents the treatment with drug-eluting-balloon, e.g., the paclitaxel-coated Sequent Please balloon (B. Braun Melsungen, Germany). This concept has been proven for different indications, e.g., in-stent restenosis and treatment of small vessels. However, in this context, no IVUS data are available so far.
Methods
PEPCAD III is a multicenter clinical trial, where 637 patients were enrolled and randomly assigned to receive either a paclitaxel-eluting balloon (Sequent Please) plus a bare metal stent (DEB) or a sirolimus-eluting stent (Cypher, Cordis Corporation, DES) to treat complex de novo lesions. IVUS was performed at follow-up in two study centers (Homburg and Hannover, Germany). We analyzed the stent and the segment proximal and distal to the stent.
Methods
PEPCAD III is a multicenter clinical trial, where 637 patients were enrolled and randomly assigned to receive either a paclitaxel-eluting balloon (Sequent Please) plus a bare metal stent (DEB) or a sirolimus-eluting stent (Cypher, Cordis Corporation, DES) to treat complex de novo lesions. IVUS was performed at follow-up in two study centers (Homburg and Hannover, Germany). We analyzed the stent and the segment proximal and distal to the stent.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
